Literature DB >> 3486159

Polyclonal activation of rat splenic lymphocytes after in vivo administration of Mycoplasma pulmonis and its relation to in vitro response.

J S Williamson, J K Davis, G H Cassell.   

Abstract

The plaque-forming cell (PFC) assay with sheep erythrocytes (SRBC) sensitized with different antigens and a 4-h tritiated thymidine pulse assay were used to determine whether polyclonal activation occurs in rats following in vivo administration of Mycoplasma pulmonis. Injection of M. pulmonis into F344 rats resulted in an increase in the number of splenic immunoglobulin M-secreting PFC that produced antibodies reactive with the trinitrophenyl hapten and with SRBC. This polyclonal response reached a peak by 72 h after injection and returned to normal levels by 96 h, at which time the specific response to M. pulmonis reached its peak. Heat treatment and preopsonization of M. pulmonis with antiserum before injection resulted in reduced numbers of PFC against M. pulmonis-sensitized SRBC, trinitrophenyl hapten-sensitized SRBC, and SRBC. The number of PFC against the three types of target cells also increased in LEW rats after immunization with M. pulmonis. The number of PFC against SRBC and staphylococcal protein A-sensitized SRBC was higher in immunized LEW rats than in immunized F344 rats. Examination of unimmunized animals also revealed that LEW rats had higher initial numbers of PFC than did F344 rats. These results showed that polyclonal activation occurs in rats following in vivo administration of M. pulmonis and that LEW rats have an inherent propensity to develop higher nonspecific responses in vivo than F344 rats.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486159      PMCID: PMC261042          DOI: 10.1128/iai.52.2.594-599.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

Review 1.  Cyclical production of antibody as a regulatory mechanism in the immune response.

Authors:  W O Weigle
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

2.  Mitogenic activity of Mycoplasma pulmonis. II. Studies on the biochemical nature of the mitogenic factor.

Authors:  Y Naot; R Siman-Tov; H Ginsburg
Journal:  Eur J Immunol       Date:  1979-02       Impact factor: 5.532

Review 3.  Regulatory effect of antibody on the immune response.

Authors:  J W Uhr; G Möller
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

4.  Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen.

Authors:  M B Rittenberg; K L Pratt
Journal:  Proc Soc Exp Biol Med       Date:  1969-11

5.  The isotype cycle: successive changes in surface immunoglobulin classes expressed by the antigen-binding B-cell population during the primary in vivo response.

Authors:  S Kanowith-Klein; E S Vitetta; R F Ashman
Journal:  Cell Immunol       Date:  1981-08       Impact factor: 4.868

6.  Mitogenicity and pathogenicity of Mycoplasma pulmonis in rats. I. Atypical interstitial pneumonia induced by mitogenic myeoplasmal membranes.

Authors:  Y Naot; S Davidson; E S Lindenbaum
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

7.  Mitogenic activity of Mycoplasma pulmonis. I. Stimulation of rat B and T lymphocytes.

Authors:  Y Naot; S Merchav; E Ben-David; H Ginsburg
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

8.  Murine respiratory mycoplasmosis in LEW and F344 rats: strain differences in lesion severity.

Authors:  J K Davis; G H Cassell
Journal:  Vet Pathol       Date:  1982-05       Impact factor: 2.221

9.  Role of antibody in the protection of mice from arthritis induced by Mycoplasma pulmonis.

Authors:  E C Keystone; A J Cunningham; A Metcalfe; M Kennedy; P A Quinn
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

10.  Protective effect of vaccination against Mycoplasma pulmonis respiratory disease in rats.

Authors:  G H Cassell; J K Davis
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

View more
  7 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  Mycoplasma pulmonis possesses a novel chemoattractant for B lymphocytes.

Authors:  S E Ross; J W Simecka; G P Gambill; J K Davis; G H Cassell
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

3.  Genotypic and phenotypic analysis of Mycoplasma fermentans strains isolated from different host tissues.

Authors:  L Campo; P Larocque; T La Malfa; W D Blackburn; H L Watson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Monoclonal antibodies that inhibit mitogenic activity of Mycoplasma pulmonis.

Authors:  Z Lapidot; R Siman-Tov; Y Naot
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  Specific and nonspecific antibody responses in different segments of the respiratory tract in rats infected with Mycoplasma pulmonis.

Authors:  J W Simecka; P Patel; J K Davis; S E Ross; P Otwell; G H Cassell
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Differences in virulence for mice among strains of Mycoplasma pulmonis.

Authors:  M K Davidson; J R Lindsey; R F Parker; J G Tully; G H Cassell
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

7.  The Use of Bacteriophages and Immunological Monitoring for the Treatment of a Case of Chronic Septicemic Cutaneous Ulcerative Disease in a Loggerhead Sea Turtle Caretta caretta.

Authors:  Whitney Greene; Benjamin Chan; Erin Bromage; Julianne H Grose; Cathy Walsh; Kaitlyn Kortright; Sue Forrest; Grace Perry; Lynne Byrd; M Andrew Stamper
Journal:  J Aquat Anim Health       Date:  2021-07-02       Impact factor: 1.625

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.